Evidence map›Paper›PMID 30651924›Full record

ArticleOncotarget2018

Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study.

Despoina Kalapanida, Flora Zagouri, Maria Gazouli, Eleni Zografos, Constantine Dimitrakakis, Spyridon Marinopoulos, Aris Giannos, Theodoros N Sergentanis, Efstathios Kastritis, Evangelos Terpos and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Despoina KalapanidaDepartment of Clinical Therapeutics, Alexandra Hospital, Medical School, University of Athens, Athens, Greece.
Flora ZagouriDepartment of Clinical Therapeutics, Alexandra Hospital, Medical School, University of Athens, Athens, Greece.
Maria GazouliDepartment of Basic Medical Sciences, Laboratory of Biology, University of Athens School of Medicine, Athens, Greece.
Eleni ZografosDepartment of Basic Medical Sciences, Laboratory of Biology, University of Athens School of Medicine, Athens, Greece.
Constantine DimitrakakisDepartment of Obstetrics and Gynaecology, Alexandra Hospital, Medical school, University of Athens, Athens, Greece.
Spyridon MarinopoulosDepartment of Obstetrics and Gynaecology, Alexandra Hospital, Medical school, University of Athens, Athens, Greece.
Aris GiannosDepartment of Obstetrics and Gynaecology, Alexandra Hospital, Medical school, University of Athens, Athens, Greece.
Theodoros N SergentanisDepartment of Clinical Therapeutics, Alexandra Hospital, Medical School, University of Athens, Athens, Greece.
Efstathios KastritisDepartment of Clinical Therapeutics, Alexandra Hospital, Medical School, University of Athens, Athens, Greece.
Evangelos TerposDepartment of Clinical Therapeutics, Alexandra Hospital, Medical School, University of Athens, Athens, Greece.
Meletios-Athanasios DimopoulosDepartment of Clinical Therapeutics, Alexandra Hospital, Medical School, University of Athens, Athens, Greece.
National and Kapodistrian University of Athens · GRAlexandra Hospital · GRBiomedical Research Foundation of the Academy of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe purpose of this study is to evaluate the role of pre-miR34a rs72631823 as potential risk factor and/or prognostic marker in patients with triple negative breast cancer.

methods114 samples of DNA from paraffin embedded breast normal tissues of patients with triple negative breast cancer and 124 samples of healthy controls were collected and analyzed for pre-miR34a rs72631823 polymorphism.

resultsPre-miR34a rs72631823 A allele was associated with increased TNBC risk both in univariate and multivariate analysis. The number of pre-miR34a rs72631823 AA subjects was very small and the association did not reach significance (

conclusionOur case-control study suggests that pre-miR34a rs72631823 A allele is associated with increased triple negative breast cancer risk.

Indexed as

biomarkermiRNApre-miR-34aSNPstriple negative breast cancer

Identifiers

PMID30651924
PMCPMC6319339
OpenAlexW2905578458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.